Winfield Associates Inc. grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 2.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 3,925 shares of the company’s stock after buying an additional 100 shares during the quarter. Winfield Associates Inc.’s holdings in Moderna were worth $514,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Truist Financial Corp raised its position in shares of Moderna by 550.6% in the 3rd quarter. Truist Financial Corp now owns 31,112 shares of the company’s stock worth $2,201,000 after acquiring an additional 26,330 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Moderna by 30.1% in the 3rd quarter. AQR Capital Management LLC now owns 75,605 shares of the company’s stock worth $5,349,000 after acquiring an additional 17,472 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Moderna by 465.9% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 41,489 shares of the company’s stock worth $2,935,000 after acquiring an additional 34,158 shares in the last quarter. Great West Life Assurance Co. Can increased its position in Moderna by 87.1% during the 3rd quarter. Great West Life Assurance Co. Can now owns 111,238 shares of the company’s stock valued at $7,860,000 after buying an additional 51,784 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in Moderna by 12.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 115,357 shares of the company’s stock valued at $8,162,000 after buying an additional 12,866 shares in the last quarter. Institutional investors and hedge funds own 51.21% of the company’s stock.
In related news, General Counsel Lori M. Henderson sold 6,600 shares of the company’s stock in a transaction on Thursday, March 11th. The stock was sold at an average price of $133.29, for a total value of $879,714.00. Following the transaction, the general counsel now directly owns 7,501 shares of the company’s stock, valued at approximately $999,808.29. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Stephen Hoge sold 5,000 shares of the company’s stock in a transaction on Friday, February 12th. The shares were sold at an average price of $185.00, for a total value of $925,000.00. Following the completion of the transaction, the president now directly owns 1,624,597 shares in the company, valued at $300,550,445. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,678,920 shares of company stock worth $826,113,177. 29.20% of the stock is owned by insiders.
Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.44). The business had revenue of $570.80 million for the quarter, compared to analyst estimates of $279.41 million. Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The business’s revenue for the quarter was up 3948.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.37) earnings per share. Equities analysts anticipate that Moderna, Inc. will post -1.5 EPS for the current year.
MRNA has been the subject of a number of analyst reports. Morgan Stanley reduced their price objective on Moderna from $215.00 to $201.00 and set an “equal weight” rating for the company in a research report on Thursday, March 4th. Piper Sandler reiterated an “overweight” rating and set a $208.00 target price on shares of Moderna in a research note on Monday, March 22nd. Bank of America reiterated a “sell” rating and set a $140.00 target price on shares of Moderna in a research note on Friday, February 26th. Wells Fargo & Company increased their target price on Moderna from $129.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, February 1st. Finally, Oppenheimer increased their target price on Moderna from $178.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, February 1st. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $150.56.
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.
See Also: Tariff
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.